November 24, 2020 — One-year results off the PIONEER III study comparing...
Cath Lab
The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).
-
-
Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual AHA...
-
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more than 276,000 patients have undergone a TAVR procedure in the United States....
-
November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system.
One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session.
News | Stents | November 24, 2020
November 24, 2020 — One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT (...
The Edwards Lifesciences Sapien 3 TAVR valve. The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients.
Feature | Heart Valve Technology | November 17, 2020
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more...
Feature | Heart Valve Technology | November 17, 2020 | Dave Fornell, Editor
November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge...
The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.
News | Cardiac Imaging | November 17, 2020
November 17, 2020 — Diagnostic imaging techniques were able to find the underlying cause of heart attack in many women...
Omega-3 fish oil supplements did not help patients after a heart attack. Getty Images
News | Pharmaceuticals | November 17, 2020
November 17, 2020 — A daily dose of omega-3 fatty acids did not reduce the risk of cardiac events, including secondary...
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to...
The FDA-Cleared XO Score is different. XO Score technology allows users to convert basic angioplasty balloons in the hospital's existing inventory into sophisticated scoring, cutting, and infusion/delivery devices.
News | Peripheral Artery Disease (PAD) | November 13, 2020
November 13, 2020 — The new U.S. Food and Drug Administration (FDA) cleared XO Score system was successfully used to...
Figure 1: PROTECT III found, when compared to intra-aortic balloon pump (IABP), Impella use led to a 29% reduction in MACCE at 90 days.
News | Hemodynamic Support Devices | November 12, 2020
November 12, 2020 — Abiomed recently announced new PROTECT III study data that demonstrates reduced rates of MACCE (...
Videos | Coronavirus (COVID-19) | November 10, 2020
Keith Ellis, M.D., is the director of cardiovascular services and the director of the Chest Pain Center at Houston...
An example of radiation dose tracking software from Imalogix showing data on cath lab angiography cases. Photo by Dave Fornell
Feature | Radiation Dose Management | November 04, 2020 | Dave Fornell, Editor
More than a decade ago, there was an alarming, rapid rise in ionizing radiation exposure in the U.S. population that...
News | Drug-Eluting Balloons | November 03, 2020
November 3, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated...
News | Robotic Systems | November 03, 2020
November 3, 2020 – Robocath, a company commercializing cardiovascular cath lab robotic systems, announced creation of...
Feature | AHA | November 20, 2020 | Dave Fornell, Editor
Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual...
Angiography with a co-registered view of pressure drops according iFR readings in a coronary vessel. The DEFINE PCI study showed patients had improved outcomes and less recurrent chest pain at one year using iFR physiologic measurements combined with landmarks shown on angiographic imaging to better guide therapy. Image by Philips Healthcare
Feature | FFR Technologies | October 30, 2020 | Dave Fornell, Editor
Fractional flow reserve (FFR) is considered the gold standard measure whether a coronary lesions needs a percutaneous...
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip was the subject of two studies, including use to aid heart transplant patients. Bottom right, the Boston Scientific Acurate neo TAVR valve performed below the Sapien 3 and CoreValve Evolut.
Feature | TCT | October 29, 2020 | Dave Fornell, Editor
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials...
